Advances in Clinical and Experimental Medicine
2016, vol. 25, nr 4, July-August, p. 709–717
Publication type: original article
The Activity of JAK/STAT and NF-κB in Patients with Rheumatoid Arthritis
1 Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Poland
2 Department of Pharmacology, Wroclaw Medical University, Poland
3 L. Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland
4 Department of Rheumatology and Internal Medicine, Wroclaw University Hospital, Poland
Background. Research is still being conducted in order to determine the mechanisms responsible for the initiation of rheumatoid arthritis (RA) as well as for its persistence and progression.
Objectives. The aim of this work was to establish the expression of the signal transducer and activator of transcription (STAT) transcription factors and the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) transcription factor in peripheral blood leukocytes and synovial fluid cells. The correlations between the activation level of the transcription factors and the activity of the disease were also analyzed.
Material and Methods. In total, the study included 34 RA patients and 19 healthy individuals as controls. The expression of NFκB, STAT1, STAT3, STAT4, STAT5 and STAT6 in peripheral blood leukocytes and synovial fluid cells was established. The immunocytochemistry method was used to determine the degree of activation of STAT and NF-κB transcription factors. For the location of the factors, primary polyclonal anti-STATs and monoclonal anti-NF-κB antibodies were used.
Results. The expression of STAT1, STAT3, STAT4, STAT5, STAT6 and NFκB was significantly higher in the group of RA patients than in the controls. No statistically significant differences were found between the expression of STATs in peripheral blood leukocytes and synovial fluid cells.
Conclusion. In comparison with the control group, the expression of the STAT and NFκB transcription factors in RA patients was higher, which may be helpful in better understanding the etiopathogenesis of the disease in the future, and may potentially have important therapeutic implications.
rheumatoid arthritis, STAT expression, NFκB expression
- Totoson P, Maguin-Gaté K, Prati C, Demougeot C: Mechanisms of endothelial dysfunction in rheumatoid arthritis: lessons from animal studies. Arthritis Res Ther 2014, 16, 202.
- Ivashkiv LB, Hu X: The JAK/STAT pathway in rheumatoid arthritis: pathogenic or protective? Arthritis Rheum 2003, 48, 2092–2096.
- Stark GR, Darnell JE: The JAK-STAT pathway at twenty. Immunity 2012, 36, 503–514.
- Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O: The activity of JAK-STAT pathways in rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin-6 levels. Rheumatology 2015, 54, 1103–1113.
- Mori T, Miyamoto T, Yoshida H, Asakawa M, Kawasumi M, Kobayashi T, Morioka H, Chiba K, Toyama Y, Yoshimura A: IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol 2011, 23, 701–712.
- Ortiz MA, Diaz-Torné C, Hernández MV, Reina D, de la Fuente D, Castellví I, Moya P, Ruiz JM, Corominas H, Zamora C, Cantó E, Sanmartí R,Juarez C, Vidal S: IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients. Clin Immunol 2015, 158, 174–182.
- Verma IM: Nuclear factor (NF)-kB proteins: therapeutic targets. Ann Rheum Dis 2004, 63, Suppl 2, 57–61.
- Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006, 65, 1558–1564.
- Malemud CJ: Intracellular Signaling Pathways in Rheumatoid Arthritis. J Clin Cell Immunol 2013, 19, 160.
- Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S, Scheller J, Garbers C: Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget 2014, 30, 2131–2148.
- Kraan TV, Gaalen F, Kasperkovitz P, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, Breedveld FC, Alizadeh AA, Verweij CL: Rheumatoid arthritis is a heterogeneous disease. Evidence for differences in the activation of the STAT-1 pathway between tissues. Arthritis Rheum 2003, 48, 2132–2145.
- Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL: Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004, 63, 233–239.
- Madej M, Sokalska-Jurkiewicz M, Nowak B, Czarny A, Zaczynska E, Wiland P: The activity of STAT3 in patients with rheumatoid arthritis. Adv Clin Exp Med 2008, 4, 405–409.
- Krause A, Scaletta N, Ji JD, Ivashkiv LB: Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002, 169, 6610–6616.
- Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM: A critical role for Stat3 signaling in immune tolerance. Immunity 2003, 19, 425–436.
- Karonitsch T, Dalwigk K, Steiner C, Blüml S, Steiner G, Kiener HP, Smolen JS, Aringer M: Interferon signals and monocytic sensitization of the interferon signaling pathway in the peripheral blood of patients with rheumatoid arthritis. Arthritis Rheum 2012, 64, 400–408.
- Walker JG, Ahern MJ, Coleman M, Weedon H, Papangelis V, Beroukas D, Roberts-Thomson PJ, Smith MD: Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66, 992–999.
- Tong G, Zhang X, Tong W, Liu Y: Association between polymorphism in STAT4 gene and risk of rheumatoid arthritis: a meta-analysis. Hum Immunol 2013, 74, 586–592.
- Liang Y, Pan H, Ye D: Therapeutic potential of STAT4 in autoimmunity. Expert Opin Ther Targets 2014, 18, 945–960.
- Jones GW, Greenhill CJ, Williams JO: Exacerbated inflammatory arthritis in response to hyperactive gp130 signalling is independent of IL-17A. Ann Rheum Dis 2013, 72, 1738–1742.
- Aerts NE, Ebo DG, Bridts CH, Stevens WJ, De Clerck LS: T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. Clin Exp Rheumatol 2010, 28, 208–214.
- Bhattacharyya S, Zhao Y, Kay T, Muglia L: Glucocorticoids target suppressor of cytokine signaling 1 (SOCS1) and type 1 interferons to regulate Toll-like receptor-induced STAT1 activation. PNAS 2011, 108, 9554–9559.
- Strickland I, Ghosh S: Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 2006, 65, Suppl 3, 75–82.
- Migita K, Izumi Y, Torigoshi T, Satomura K, Izumi M, Nishino Y, Jiuchi Y, Nakamura M, Kozuru H, Nonaka F, Eguchi K, Kawakami A, Motokawa S: Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway inrheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol 2013, 174, 356–363.
- Scott LJ: Tofacitinib: A review of its use in adult patients with rheumatoid arthritis. Drugs 2013, 73, 857–874.
- Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS: The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 2015, 74, 1311–1316.